I

Infervision

Health Tech & Medtech · Philadelphia, United States · Founded 2015

In 2016, Kuan Chen and Shaokang Wang founded Infervision in Beijing, China, with a vision to revolutionize the medical imaging industry using artificial intelligence. Their goal was to enhance the accuracy and efficiency of medical image diagnosis, addressing a critical need in healthcare. Infervision quickly gained traction by developing AI-based solutions that assist radiologists in interpreting medical images more accurately and swiftly. This innovation not only improved diagnostic outcomes but also alleviated the workload of medical professionals. The company experienced significant growth, attracting attention from major investors. In 2021, Infervision completed a Series D funding round, raising approximately USD 139 million from prominent investors, including Goldman Sachs and Z-Park Fund. This funding was pivotal in expanding their research and development capabilities and scaling their operations globally. Infervision's journey reached another milestone as they prepared for an Initial Public Offering (IPO) in Hong Kong, aiming to raise about USD 300 million. This move was a testament to their success and ambition to further cement their position as a leader in the AI medical imaging field. Today, Infervision stands at the forefront of medical AI technology, continuously innovating to improve patient care and support healthcare professionals worldwide. Their story is a remarkable example of how technology can transform industries and address pressing global challenges.